--- title: "CurveBeam AI Adds Veteran Orthopaedic Executive to Board for Global Growth Push" type: "News" locale: "en" url: "https://longbridge.com/en/news/279682065.md" description: "CurveBeam AI Ltd. has appointed Patrick Fisher, a veteran in the orthopaedic industry, as an independent non-executive director to enhance its strategic capabilities in the U.S. market. Fisher's experience from companies like Orthofix and Stryker will support the rollout of CurveBeam's weight-bearing CT technology. His role includes driving partnerships and market adoption for growth both in the U.S. and internationally. The current analyst rating for CurveBeam AI stock (AU:CVB) is a Hold with a price target of A$0.15." datetime: "2026-03-18T22:26:41.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/279682065.md) - [en](https://longbridge.com/en/news/279682065.md) - [zh-HK](https://longbridge.com/zh-HK/news/279682065.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/279682065.md) | [繁體中文](https://longbridge.com/zh-HK/news/279682065.md) # CurveBeam AI Adds Veteran Orthopaedic Executive to Board for Global Growth Push ### Claim 70% Off TipRanks Premium - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Curvebeam AI Ltd. ( (AU:CVB) ) has shared an update. CurveBeam AI has appointed U.S.-based orthopaedic industry veteran Patrick Fisher as an independent non-executive director, adding extensive leadership experience from Orthofix, Stryker and Wright Medical. Fisher’s background in global orthopaedic markets, capital equipment deployment and surgeon engagement is expected to support the broader rollout of CurveBeam’s weight-bearing CT technology. The company’s chair said Fisher’s appointment strengthens strategic capabilities in the key U.S. growth market as CurveBeam executes its next phase of commercial expansion. Fisher, who will receive a mix of cash fees and time-vested share rights, highlighted plans to help drive partnerships, market adoption and sustained growth in the U.S. and internationally. The most recent analyst rating on (AU:CVB) stock is a Hold with a A$0.15 price target. To see the full list of analyst forecasts on Curvebeam AI Ltd. stock, see the AU:CVB Stock Forecast page. **More about Curvebeam AI Ltd.** CurveBeam AI Limited is a medical imaging company that develops, manufactures and sells specialised CT scanners combined with AI-enabled SaaS clinical assessment tools for musculoskeletal care. Its flagship HiRise system performs weight-bearing and traditional CT scans, targeting orthopaedic and related markets from bases in Melbourne and Hatfield, Pennsylvania. **Average Trading Volume:** 851,116 **Technical Sentiment Signal:** Sell **Current Market Cap:** A$27.71M See more insights into CVB stock on TipRanks’ Stock Analysis page. ### Related Stocks - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md) - [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md) - [Direxion Daily S&P Biotech Bull 3X ETF (LABU.US)](https://longbridge.com/en/quote/LABU.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md) - [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md) - [Beam Therapeutics Inc. (BEAM.US)](https://longbridge.com/en/quote/BEAM.US.md) - [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md) - [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md) ## Related News & Research - [Trevi Therapeutics Maps Phase III Path and Runway](https://longbridge.com/en/news/279703997.md) - [Insmed Lung Infection Therapy Data Impresses, Analyst Sees Approval Path](https://longbridge.com/en/news/280195463.md) - [BUZZ-CytomX retreats ahead of planned $250 mln equity raise after promising cancer drug data](https://longbridge.com/en/news/279463333.md) - [Structure Therapeutics Posts 15%+ Weight Loss in ACCESS II for Oral GLP-1 Aleniglipron, Eyes Phase III](https://longbridge.com/en/news/279532083.md) - [Red Light Holland Deploys Kala Bio AI Platform to Advance Psilocybin Drug PEX010](https://longbridge.com/en/news/279611034.md)